Phase 2 Brain Cancer Trial, Recruiting NCT06620380 Sponsor: University of Zurich Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT06620380
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older at the time of signing the consent form, of any gender
  • People whose general health and ability to function meets a minimum level as measured by a standard medical scoring tool (Karnofsky performance status of 60 or above — confirm with trial site)
  • People who have limited remaining standard treatment options, as determined by their treating doctor, with no restriction on how many previous treatments they have had
  • People whose cancer has a specific genetic change that can be targeted by a drug must have already received that targeted drug, with no further targeted options remaining
  • People who have a medical reason to have brain surgery for a suspected brain metastasis (cancer that has spread to the brain)
  • People whose brain metastasis has been confirmed by laboratory analysis of tissue taken during surgery performed after signing the trial consent form
  • People with any type of primary cancer, including breast cancer, lung cancer, melanoma, or others — having more than one primary cancer is also allowed
  • People who have adequate bone marrow, kidney, and liver function, confirmed by tests done before surgery
  • Women who could potentially become pregnant, including those who had their last period within the last 2 years, must have a negative pregnancy test at screening
  • People who are able to understand what the study involves, sign a written consent form, and agree to follow the study requirements and attend required appointments

Who may not be able to join:

  • People whose cancer outside the brain is rapidly worsening
  • People who are unable to have a brain MRI scan
  • People whose brain metastases are progressing in a way that would require whole-brain radiotherapy after surgery (targeted radiotherapy to a specific area after surgery is permitted)
  • People whom the trial investigator believes are unlikely to follow the study procedures and requirements
  • People who intend to become pregnant during the study
  • People who are currently pregnant
  • People who are breastfeeding and do not agree to stop nursing before starting any treatment in the study
  • Sexually active people who could potentially father or become pregnant and are not willing to use effective contraception during the study, and men who do not agree to avoid donating sperm during the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +41 44 255 38 99

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
12 September 2025
Est. completion
1 September 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov